Accueil du site > Revue de presse > Sources d’information > Médical > AIDSMeds.com
AIDSMeds.com
http://www.aidsmeds.com/news/TopStories.htm
Fil d’information de Reuters Health (en anglais) sur l’actualité thérapeutique du VIH.
-
FDA Panel: Qutenza Pain Patch for Neuropathy Not Ready for Approval
A U.S. Food and Drug Administration advisory committee voted unanimously against recommending the approval of a novel patch applied to the soles of the feet to remedy pain associated with neuropathy in people living with HIV. Though the patch is commercially available for the treatment of (...)
-
Antibiotics Losing Battle Against Gonorrhea
The last line of defense against gonorrhea is losing its effectiveness against the gonorrhea, according to a new article published February 9 in the The New England Journal of Medicine. With no new antibiotics effective against the sexually transmitted infection (STI) on the horizon, Gail (...)
-
Merck Warns of Victrelis and HIV Protease Inhibitor Interactions
The hepatitis C protease inhibitor Victrelis (boceprevir) has some significant drug-drug interactions with common Norvir (ritonavir)?boosted protease inhibitor (PI) combinations, according to preliminary data from a clinical trial and a warning issued to health care providers by Merck on (...)
-
Spinal Cord Stimulation Shows Potential for Peripheral Neuropathy
Electrical stimulation of the spinal cord markedly reduced peripheral neuropathy (PN)associated pain in a man living with HIV who didn’t respond to more conventional PN therapies, according to a February 5 presentation at the 6th World Congress of the World Institute of Pain in Miami and (...)
-
CDC Recommends HPV Vaccine for Boys and Young Men, Hep B Vaccine for Diabetics
It’s official: All males between 11 and 21 years of age should be vaccinated against human papillomavirus (HPV), a leading cause of oral, genital and anal cancers, according to new U.S. Centers for Disease Control and Prevention guidelines published February 3 in the health agency’s Morbidity and (...)
-
Isentress, Intelence, Prezista Regimen Goes the Distance for HIV Treatment Veterans
A drug regimen containing Isentress (raltegravir), Intelence (etravirine) and Norvir (ritonavir)boosted Prezista (darunavir) has been shown to be “highly potent and durable in terms of efficacy and safety” in a French clinical trial involving heavily treatment-experienced people living with HIV. (...)
-
Awareness, Testing Needed to Curb Hep C Infections Among HIV-Positive Gay Men
A new report by the National AIDS Trust (NAT), a leading HIV organization in the United Kingdom, concludes that much more needs to be done to address the burgeoning epidemic of hepatitis C virus (HCV) infection among gay men living with (...)
-
Awareness, Testing Needed to Curb Hep C Infections Among HIV-Positive Gay Men
A new report by the National AIDS Trust (NAT), a leading HIV organization in the United Kingdom, concludes that much more needs to be done to address the burgeoning epidemic of hepatitis C virus (HCV) infection among gay men living with (...)
-
Awareness, Testing Needed to Curb Hep C Infections Among HIV-Positive Gay Men
A new report by the National AIDS Trust (NAT), a leading HIV organization in the United Kingdom, concludes that much more needs to be done to address the burgeoning epidemic of hepatitis C virus (HCV) infection among gay men living with (...)
-
Alcohol Treatment Boosts Hep C Cure Rates Among Drinkers
People who drink—even heavily—can successfully undergo treatment for hepatitis C virus (HCV) if they’re provided with individualized, multidisciplinary care that also addresses their alcohol use, according to a study published in the February 2012 issue of Journal of (...)